Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIPAC2: PIPAC and ePIPAC with Paclitaxel for Peritoneal Carcinomatosis
NCT05395910Phase 1Recruiting
- Sponsor
- National University Hospital
- Start
- Aug 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of paclitaxel in peritoneal carcinomatosis (PC) (2 arms), sponsored by National University Hospital. Primary endpoints: Dose Limiting Toxicities and Adverse Events. Started Aug 2023; status: recruiting.
02
Drugs
paclitaxel
03
Conditions
peritoneal carcinomatosis (PC)
Beyond the preview
Go deeper on NCT05395910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05395910.